Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A one-year, Phase II, randomized, double-blind, placebo-controlled, safety and efficacy trial of edasalonexent in non-ambulatory boys and men affected by Duchenne Muscular Dystrophy

Next Previous
Trial Profile

A one-year, Phase II, randomized, double-blind, placebo-controlled, safety and efficacy trial of edasalonexent in non-ambulatory boys and men affected by Duchenne Muscular Dystrophy

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 17 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Edasalonexent (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Adverse reactions; Pharmacokinetics

Most Recent Events

  • 23 Jan 2026 According to a BioCryst Pharmaceuticals media release, Astria Therapeutics has been acquired and merged into BioCryst Pharmaceutical.
  • 10 Aug 2020 According to a Catabasis Pharmaceuticals media release, the the trial is expected to initiate in 2021.
  • 10 Jan 2020 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top